Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial.

Objective: To determine whether infusions with intravenous immunoglobulin (IVIg) during early pregnancy increase live birth rate in women with secondary recurrent miscarriage compared with placebo.

Design: A single-centre, randomised, double-blind, placebo-controlled trial.

Setting: A tertiary centre for recurrent miscarriage in Copenhagen, Denmark.